In October 2026, Nuance Pharma announces the first patient dosed in the REACH Phase III trial, a randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of ...
Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral ...
Backed by GSK, Pfizer and Sanofi, the Cascade initiative will integrate single-cell sequencing and protein data to strengthen predictive models of human immune responses.
Alkermes plc announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive ...
Obesity was the most searched therapeutic area of 2026, and for most readers the story still has two names in it. Semaglutide ...
The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically ...
Accord now holds two pegfilgrastim biosimilars in one market, its in-house Ennumo and the acquired Udenyca. Owning both the ...
Enhertu ® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment ...
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple ...
Despite missing primary endpoints, the endocannabinoid modulator demonstrated encouraging pain score improvements in subgroup ...
Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial ...
TJ Biopharma Doses First Patient in Phase I Trial of CLDN6 × 4-1BB Bispecific Antibody for Advanced Solid Tumours ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results